Rhelion Life Sciences launches ibogaine stability program

Rhelion Life Sciences Corp. has announced that its subsidiary, Filament Health Corp., is initiating a stability program for IBEX011, a botanical ibogaine drug candidate. This move addresses the increasing demand for pharmaceutical-grade ibogaine suitable for regulated clinical research, according to a recent announcement.

Stability program for IBEX011

Filament Health is focusing on developing a standardized ibogaine supply through its stability program for IBEX011. This drug candidate is a total-alkaloid extract derived from Tabernanthe iboga, utilizing Filament's proprietary extraction and stabilization technologies. The company aims to leverage its expertise, previously demonstrated with its psilocybin candidate PEX010, to establish a reliable ibogaine supply chain.

Regulatory context

Despite its potential, ibogaine remains a Schedule I substance in the United States, restricting its clinical use. However, recent regulatory shifts may change this landscape. An Executive Order in April 2026 called for accelerating treatments for serious mental illnesses, explicitly mentioning ibogaine. This has led to increased funding and state-level initiatives supporting ibogaine research, according to Rhelion Life Sciences.

Why it matters

The stability program for IBEX011 is significant due to the growing interest in ibogaine as a treatment for various mental health conditions. With the U.S. regulatory environment evolving, there is a pressing need for a dependable supply of pharmaceutical-grade ibogaine. Filament Health's proven track record with PEX010 positions it well to meet this demand, potentially giving it an early-mover advantage in the emerging ibogaine market.

Filament Health's progress with IBEX011 could play a crucial role in addressing the current unmet demand for standardized ibogaine in clinical research settings.